<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836429</url>
  </required_header>
  <id_info>
    <org_study_id>I 767720</org_study_id>
    <nct_id>NCT04836429</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease</brief_title>
  <official_title>Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) With Pleural Disease - Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial evaluates the side effects of intraoperative photodynamic therapy with&#xD;
      porfimer sodium in enhancing the response to immunotherapy with an immune checkpoint&#xD;
      inhibitor drug in patients with non-small cell lung cancer with pleural disease. Photodynamic&#xD;
      therapy is a technique that that works by combining a photosensitizing agent (porfimer sodium&#xD;
      in this trial) and an intense light source to kill tumor cells. Photodynamic therapy may&#xD;
      decrease the patients' symptoms and improve their quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAE)</measure>
    <time_frame>28 days post study-related immunotherapy</time_frame>
    <description>Will be determined by recording the occurrence of SAE during the first 28 days post study-related immunotherapy. The SAE will be evaluated using the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>assessed up to 2 years</time_frame>
    <description>Will utilize Kaplan-Meier curves to descriptively examine dose level differences and generate summary statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>assessed up to 2 years</time_frame>
    <description>Will utilize Kaplan-Meier curves to descriptively examine dose level differences and generate summary statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the immune phenotype of peripheral blood CD8+ T cells</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Will be analyzed using a repeated measures analysis-of-variance (ANOVA) model with a factor for dose level time and a dose level by time interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in platelet-to-lymphocyte ratio</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Will be analyzed using a repeated measures ANOVA model with a factor for dose level, time and a dose level by time interaction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Lung Non-Small Cell Carcinoma</condition>
  <condition>Pleural Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment (porfimer sodium, photodynamic therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Porfimer Sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (porfimer sodium, photodynamic therapy)</arm_group_label>
    <other_name>87806-31-3</other_name>
    <other_name>CL-184116</other_name>
    <other_name>Dihematoporphyrin Ester</other_name>
    <other_name>Photofrin II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Video-Assisted Thoracic Surgery</intervention_name>
    <description>Undergo VATS</description>
    <arm_group_label>Treatment (porfimer sodium, photodynamic therapy)</arm_group_label>
    <other_name>VATS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photodynamic Therapy</intervention_name>
    <description>Undergo photodynamic therapy</description>
    <arm_group_label>Treatment (porfimer sodium, photodynamic therapy)</arm_group_label>
    <other_name>PDT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoperative PDT</intervention_name>
    <description>Subjects will receive one course of light therapy at the time of surgery</description>
    <arm_group_label>Treatment (porfimer sodium, photodynamic therapy)</arm_group_label>
    <other_name>intra-operative photo dynamic therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer (NSCLC) with pleural disease and&#xD;
             PDL1 expression &lt; 50%&#xD;
&#xD;
          -  The patient should be considered a candidate for chemoimmunotherapy by the treating&#xD;
             medical oncologist&#xD;
&#xD;
          -  Age &gt;= 18 years of age&#xD;
&#xD;
          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) score of 0 - 1&#xD;
&#xD;
          -  Subjects of child-bearing potential must agree to use adequate contraceptive methods&#xD;
             (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry&#xD;
             and for 6 months after surgery. Should a woman become pregnant or suspect she is&#xD;
             pregnant while she or her partner is participating in this study, she should inform&#xD;
             her treating physician immediately&#xD;
&#xD;
          -  The subject must understand the investigational nature of this study and sign an&#xD;
             Independent Ethics Committee/Institutional Review Board approved written informed&#xD;
             consent prior to receiving any study related procedure&#xD;
&#xD;
          -  Platelet count &lt; 100,000&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study or those who have not&#xD;
             recovered from adverse events due to agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Patients with untreated or symptomatically unstable treated brain metastases should be&#xD;
             excluded from this clinical trial because of their poor prognosis and because they&#xD;
             often develop progressive neurologic dysfunction that would confound the evaluation of&#xD;
             neurologic and other adverse events. Patients with treated and stable brain metastases&#xD;
             (at least 28 days from last radiotherapy treatment) are eligible as long as steroids&#xD;
             are not required for symptom management&#xD;
&#xD;
          -  Patients with porphyria, or with known hypersensitivity to porphyrins or&#xD;
             porphyrin-like compounds&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1500&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; lower level of normal (LLN)&#xD;
&#xD;
               -  Total bilirubin &gt; 2 mg/dL&#xD;
&#xD;
               -  Creatinine clearance &lt; 60 mL/min (Cockcroft Gault equation)&#xD;
&#xD;
               -  Alkaline phosphatase (hepatic) &gt; 3 times the upper normal limit (SGPT) &gt; 3 times&#xD;
                  the upper normal limit&#xD;
&#xD;
               -  NOTE: Roswell Park clinical lab blood chemistry is performed on plasma unless&#xD;
                  otherwise indicated&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant or nursing female subjects&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the Investigator's opinion deems the subject an unsuitable&#xD;
             candidate to receive porfimer sodium&#xD;
&#xD;
          -  Received an investigational agent within 30 days prior to enrollment&#xD;
&#xD;
          -  History of, or active autoimmune disorder, requiring systemic steroids or&#xD;
             immunosuppressive agents. Exceptions allowed: patients with autoimmune dermatologic&#xD;
             conditions not requiring systemic steroids or immunosuppressive agents (e.g. vitiligo,&#xD;
             eczema, etc.), endocrine-related autoimmune conditions receiving appropriate hormonal&#xD;
             supplementation. Use of immunosuppressant drugs such as steroids, azathioprine,&#xD;
             tacrolimus, cyclosporine, etc. is not permitted within 4 weeks before recruitment&#xD;
             (exception allowed is use of steroids as hormone replacement therapy or as supportive&#xD;
             medication e.g. anti-emesis, contrast allergy, pre-medication, etc. or other&#xD;
             short-course therapy less than 2 weeks continuously within 4 weeks of study treatment)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>â€¢ Saikrishna Yendamuri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ASK Roswell</last_name>
    <phone>1-800-767-9355</phone>
    <email>askroswell@roswellpark.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saikrishna S. Yendamuri</last_name>
      <phone>716-845-8675</phone>
      <email>Sai.Yendamuri@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Saikrishna S. Yendamuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pleural Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

